• LAST PRICE
    1.4900
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (2.0548%)
  • Bid / Lots
    1.4900/ 9
  • Ask / Lots
    1.5000/ 11
  • Open / Previous Close
    1.4600 / 1.4600
  • Day Range
    Low 1.4514
    High 1.5000
  • 52 Week Range
    Low 1.2200
    High 2.2600
  • Volume
    24,681
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.46
TimeVolumeUBX
09:32 ET40341.46
09:43 ET1841.46
09:52 ET3001.46
10:32 ET20001.46
10:33 ET20001.4641
10:39 ET10001.46
10:46 ET7001.4514
11:02 ET2001.4575
11:40 ET6001.4699
11:49 ET31021.4605
12:32 ET3001.4775
12:52 ET1001.49
01:15 ET5001.4863
01:42 ET1001.49
01:50 ET3931.48
02:06 ET4001.48962
02:08 ET13741.4907
02:11 ET4311.49
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesUBX
UNITY Biotechnology Inc
24.6M
-0.8x
---
United StatesNRSN
Neurosense Therapeutics Ltd
24.5M
-1.7x
---
United StatesRNXT
RenovoRx Inc
24.5M
-1.7x
---
United StatesALTS
ALT5 Sigma Corp
24.3M
-0.5x
---
United StatesLSTA
Lisata Therapeutics Inc
25.0M
-1.2x
---
United StatesNRBO
NeuroBo Pharmaceuticals Inc
23.2M
-0.6x
---
As of 2024-10-07

Company Information

Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.

Contact Information

Headquarters
285 EAST GRAND AVENUESOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-416-1192
Fax
302-655-5049

Executives

Chief Executive Officer, Director
Anirvan Ghosh
Chief Financial Officer, Head - Corporate Development
Lynne Sullivan
Chief Legal Officer and Head - Operations
Alexander Nguyen
Chief Strategy Officer
Alicia Tozier
Lead Independent Director
Paul Berns

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$24.6M
Revenue (TTM)
$0.00
Shares Outstanding
16.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.82
EPS
$-1.80
Book Value
$1.69
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.